Clinical trial · Observational
Compliance to a Hormone Therapy Regimen in Breast Cancer
Adherence to Endocrine Therapy in Women With Breast Cancer in Clinical Practice Settings
NCT00666822CI-TRIAL-00020804completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
RATIONALE: Understanding how well patients comply with their treatment regimen may help doctors plan the best treatment and ongoing care. PURPOSE: This clinical trial is studying whether patients comply with their hormone therapy regimen in women with estrogen receptor-positive stage I, stage II, or stage IIIA breast cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| compliance monitoring | Behavioral | — | UNRESOLVED |
| medical chart review | Other | — | UNRESOLVED |
| questionnaire administration | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (4)
- measure
- Adherence to endocrine therapy
- timeFrame
- at 5 yrs
- measure
- Effects of categorical predictors of compliance
- timeFrame
- at 5 yrs
- measure
- Comparison of the means of each continuous predictor between compliers and non-compliers
- timeFrame
- at 5 yrs
- measure
- Effects of continuous and categorical variables on compliance, controlling for other factors including age at diagnosis, race, education, and type of surgery
- timeFrame
- 5 yrs
Secondary outcomes (2)
- measure
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
DISEASE CHARACTERISTICS: * Women diagnosed with breast cancer * Stage I-IIIA disease * Estrogen receptor (ER)-positive disease * Must have begun prescribed hormonal therapy between December 2000 and December 2002 * No prior history of breast cancer PATIENT CHARACTERISTICS: * Female * Menopausal status not specified * Able to read and understand English PRIOR CONCURRENT THERAPY: * See Disease Characteristics * Prior breast surgery, axillary surgery, and radiotherapy to the breast or chest wall allowed
References
Publications (0)
Data not yet available
No reference posted for this study.